Essays in biochemistry volume 40 - subject index [pdf]

Bcl-2-associated gene product-1 (BAG-1), 49 acetylation, 3, 5–6, 74, 79, 80, 81, 84–85, breast cancer, 96–97, 130–132, 158, 159, activation function, 3, 29, 31–33, 34, 35, 36–37, 68, 109, 110, 113, 124, 125, 170 cancer, 96–97, 130–132, 133–134, 158, 159, CAR (see constitutive androstane receptor) Aha (see activator of heat-shock protein AHC (see adrenal hypoplasia congenita) transcription factor (see CUOP-TF) AIS (see androgen-insensitivity syndrome) ChIP (see chromatin immunoprecipitation aldosterone (see mineralocorticoid) CHIP (see C-terminus of heat-shock-protein- chromatin, 6, 7, 30, 74, 75, 79, 80–81, 91–92, amiloride-sensitive sodium channel, 139, androgen receptor, 4, 6, 7, 8, 60, 61, 67–68, co-activator, 4, 7, 8, 17, 30, 106, 113, 117, androgen-insensitivity syndrome, 125–130 (see also nuclear receptor co-activator; ASSC (see amiloride-sensitive sodium channel) ERR (see oestrogen-related receptor) ESCS (see enhanced S-cone syndrome) co-repressor, 4, 7, 8, 17, 30, 90–94, 95, (see also ligand-dependent nuclear familial Parkinson’s disease, 185–186 fluorescence recovery after photo-bleaching fushi tarazu transcription factor 1 (FTZ-F1), CRC (see chromatin remodelling complex) CRH (see corticotropin-releasing hormone) generalized resistance to thyroid hormone, glucocorticoid, 6, 7, 138, 139, 142, 144, 147, glucocorticoid receptor, 2, 4–7, 31, 32, 34, glucocorticoid resistance, 138, 143–145, 147, DNA-binding domain, 2–5, 7, 8, 12, 16, 28, 122–125, 127–128, 139–140, 145, 158, G-protein-coupled receptor, 110–112, 114 GPCR (see G-protein-coupled receptor) GRE (see glucocorticoid response element) GRTH (see generalized resistance to thyroid heat-shock protein 70, 42, 43, 45–49, 52, 53, insulin resistance, 171, 178–179, 180, 181 Kennedy disease (see spinobulbar muscular hepatocyte nuclear factor 4␣, 13, 16, 19, 171, LCoR (see ligand-dependent nuclear receptor ligand-activated nuclear receptor (see consti- some-proliferator-activated receptor ␥; HNF4␣ (see hepatocyte nuclear factor 4␣) ligand-binding domain, 2–5, 7, 8, 12, 16, 18, Hop (see heat-shock protein organizer 19, 20, 28, 31, 34–35, 36, 37, 42, 106, (see also androgen-insensitivity syn- ligand-binding pocket, 5, 143, 145, 150, 152 hormone-response element, 4, 12, 33–34, loss-of-function mutation, 138, 147, 148, 149 HPA axis (see hypothalamic/pituitary/ HRE (see hormone-response element) hypothalamic/pituitary/adrenal axis, 138, MAPK (see mitogen-activated protein kinase) maturity onset diabetes of the young type 1, mineralocorticoid, 138, 139, 141, 142, 143, oestrogen, 6, 12, 18, 107, 112–117, 133, 134, oestrogen receptor, 2, 4, 6–8, 60, 61, 63–69, mitogen-activated protein kinase, 6, 107, oestrogen receptor ␣ (ER␣), 158–164 MNAR (see modulation of non-genomic oestrogen receptor ␤ (ER␤), 158–164 MODY1 (see maturity onset diabetes of orphan nuclear receptor, 4, 5, 8, 12, 18, MR (see mineralocorticoid receptor) NCoR (see nuclear receptor co-repressor) negative response element, 7, 97–98, 101 p300/CBP-associated factor (pCAF), 17, 18, NGFI-B (see nerve growth factor inducible pCAF (see p300/CBP-associated factor) NTD (see N-terminal transactivation domain) N-terminal transactivation domain, 3, 28–33, peroxisome-proliferator-activated receptor ␥, PHA1 (see pseudohypoaldosteronism type 1) phosphoinositide 3-kinase/Akt signalling path- phosphorylation, 3, 5–6, 32, 74, 79, 81, 85, nuclear receptor co-repressor, 17, 91–92, PI 3-kinase (see phosphoinositide 3- NUR-related factor 1, 18, 173, 174, 185–186 PLR (see PPAR␥ ligand resistance) PNR (see photoreceptor-specific nuclear polypyrimidine tract binding protein-associat- receptor-interacting protein, 91, 93, 140 post-translational modification (see acetyla- PPAR␥ (see peroxisome-proliferator-activat- retinoid-related orphan receptor, 4, 13, 18 PPAR␥ ligand resistance (PLR), 177, 180 retinoid X receptor, 3, 4, 34, 60, 62, 66, 171, PPIase (see peptidylprolyl isomerase) PPP1R3A (see protein phosphatase 1 RIP140 (see receptor-interacting protein 140) ROR␣ (see retinoid-related orphan receptor) SBMA (see spinobulbar muscular atrophy) PRMT (see protein arginine methyl- progesterone, 6, 12, 67–112, 116–117, 143, progesterone receptor, 2, 4, 6, 60, 61, 63, SHBG (see sex-hormone-binding globulin) SHP (see small heterodimer partner) silencing mediator of repressed transcription prostate cancer, 96, 130, 132, 133–134, silencing mediator of retinoic acid and thyroid protein arginine methyltransferase, 77, 79, 81 single-nucleotide polymorphism, 163–164 small heterodimer partner, 171, 174, 182, 183 protein phosphatase 1 regulatory subunit 3A, small unique nuclear receptor co-repressor, PRTH (see pituitary resistance to thyroid SNP (see single-nucleotide polymorphism) PSF (see polypyrimidine tract binding protein- SRC (see steroid receptor co-activator) Src tyrosine kinase, 6, 107, 108–109, 111, (see also androgen; ecdysone; glucocorti- transactivation domain (see activation function) steroidogenic factor 1, 4, 13, 19, 171, 174, transcription factor (see also activator protein steroid receptor (see androgen receptor; transcription co-activator (see co-activator) transcription co-repressor (see co-repressor) steroid receptor co-activator, 77, 83, 85, SUN-CoR (see small unique nuclear receptor TAF (see TATA-box-binding-protein- TATA-box-binding protein (TBP), 7, 17, 75, vascular protection by oestrogen, 112, 116 TATA-box-binding-protein-associated factor, TBP (see TATA-box-binding protein) vitamin D receptor, 3–5, 7, 13, 18, 60–61, thyroid hormone receptor, 2–5, 7, 8, 66 thyroid hormone receptor ␣ (TR␣), 173, 175 Xenopus oocyte maturation, 107, 108, thyroid hormone receptor ␤ (TR␤), 173, zinc finger, 33, 122, 124, 170, 172–173

Source: http://essays.biochemistry.org/bsessays/040/index.pdf